Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER